Key takeaways:
- There was no important distinction in obesity-related most cancers incidence between GLP-1 remedy and bariatric surgical procedure in a real-world cohort.
- Mechanistic research and analysis in bigger populations are wanted.
Adults with weight problems utilizing a GLP-1 have the same danger for obesity-related cancers as those that endure bariatric surgical procedure, researchers reported in information offered on the European Congress on Weight problems and revealed in eClinicalMedicine.
In a retrospective research of digital medical information within the Clalit database in Israel, researchers matched a gaggle of three,178 adults with weight problems and diabetes who began GLP-1 remedy with 3,178 adults who underwent bariatric surgical procedure. Each teams had comparable incidence of obesity-related cancers, with GLP-1s having a 41% direct impact past weight reduction on obesity-related most cancers danger discount.
“The outcomes level on the existence of further pathways past weight reduction during which GLP-1s contribute to the decreased danger for obesity-related most cancers,” Yael Wolff Sagy, PhD, head of the analysis division within the department of planning and technique at Clalit Well being Providers in Israel, instructed Healio.
Yael Wolff Sagy
Adults aged 24 years or older with diabetes and weight problems who underwent an preliminary bariatric surgical procedure or began GLP-1 use from 2010 to 2018 had been included within the research (61.1% girls; imply age, 52.3 years). Contributors had been matched by age, intercourse, baseline BMI, remedy initiation 12 months and smoking standing. Comply with-up continued by way of 2023. Weight problems-related cancers included a number of myeloma, meningioma, adenocarcinoma of the esophagus, abdomen, colorectal, liver or bile duct, gallbladder, pancreas, corpus uteri, ovary, renal-cell kidney, thyroid and postmenopausal breast most cancers.
Most adults within the bariatric surgical procedure group underwent a sleeve gastrectomy (49%) or gastric bypass (40%). Of the GLP-1 group, 73% initiated liraglutide (Victoza/Saxenda, Novo Nordisk).
The incidence charge of obesity-related cancers was 5.64 per 1,000 person-years within the GLP-1 group in contrast with 5.76 per 1,000 person-years for adults present process bariatric surgical procedure. There was no considerably elevated danger for obesity-related cancers amongst adults utilizing a GLP-1 (HR = 1.11; 95% CI, 0.86-1.44).
The typical most BMI discount noticed throughout follow-up was 31.1% with bariatric surgical procedure in contrast with 12.9% with GLP-1 use. P.c most BMI change was related to obesity-related most cancers incidence (HR = 1.02; 95% CI, 1.01-1.03). When BMI change was added as a possible mediator, GLP-1 use was related to decrease danger for obesity-related most cancers in contrast with bariatric surgical procedure (HR = 0.59; 95% CI, 0.41-0.85).
Researchers additionally assessed HbA1c as a possible mediator, however discovered it had no mediation impact.
“Outcomes from in vitro and preclinical research to this point recommend anti-inflammatory properties of GLP-1s that will modulate the immune system,” Sagy stated. “But, additional analysis, together with mechanistic research, are wanted to establish attainable anti-inflammatory results of GLP-1s.”
Sagy added that bigger cohort research carried out in different nations are wanted to validate the research’s findings.
Reference:
Sagy YW, et al. EClinicalMedicine. 2025;doi:10.1016/j.eclinm.2025.103213.
For extra data:
Yael Wolff Sagy, PhD, will be reached at yaelwo@clalit.org.il.
Sources/Disclosures
Collapse
Sagy YW, et al. Poster Summary 0036. Introduced at: European Congress on Weight problems, Might 11-14, 2025; Malaga, Spain.
Disclosures:
Sagy experiences no related monetary disclosures. Please see the research for all different authors’ related monetary disclosures.
